Rethinking Phase IV: Congress Wants to Get Tough on Post-Marketing Requirements, but FDA May Soften the Blow
This article was originally published in RPM Report
Executive Summary
Congress is ready to grant FDA more authority over Phase IV studies-over the objections of both agency officials and drug sponsors. But if FDA is right, improvements to the designs of post-marketing studies may help reduce the impact on industry.
You may also be interested in...
Merck's Cordaptive: Just Another Cholesterol Combo, or More?
At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
Merck's Cordaptive: Just Another Cholesterol Combo, or More?
At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill
The world of post-approval research is going to get more public, more crowded, and more dangerous to pharma. Post-marketing surveillance, transparent clinical trial results and mandated post-approval studies mean the traditional world of marketing-oriented Phase IV is about to change dramatically.